# Verixa · India Founder-Led Email Templates v1.1

**Version:** v1.1 · 23 June 2026 (supersedes v1.0 4-track × 5-touch architecture per founder brief)
**Use:** Founder-led 1-to-1 cold outreach to India GMP QA / RA / Ops leaders
**Sender:** Vimal Veereshwarayya · `vimalv@verixa.ai`
**Reduction discipline:** 2 primary email variants · phone script · post-call follow-up · NO RA / Annex 22 / multi-site / quarterly nurture / 5-touch
**Status:** Ready after contact verification and buyer-asset cleanup

---

## What changed from v1.0

| v1.0 (archived) | v1.1 (current) | Why |
|---|---|---|
| 4 persona tracks × 5 touches = 20 variants | 2 primary email variants (QA leader · CEO/MD) | Founder discipline: "too much for founder-led India outreach · increases inconsistency · need fewer sharper messages" |
| RA variant track C | KILLED · revisit only after market feedback | Drifts from main wedge |
| Multi-site / operations variant track D | KILLED · revisit only after market feedback | Drifts from main wedge |
| Annex 22 cold hook | KILLED · use only if prospect is already discussing AI governance | "Sounds opportunistic or too regulatory-current as cold hook" |
| T5 quarterly nurture | KILLED · revisit only after market feedback | "Five-touch sequence is too much" |
| T4 re-engagement | KEPT but tightened | "Don't chase past T4 without explicit do-not-contact" |
| WhatsApp default | KILLED · use only after relationship · referral · permission | "Do not treat WhatsApp as default" |

---

## EMAIL 1 · QA / Quality leader (primary variant)

**For:** Head of Quality · VP Quality · Quality Director · Cluster QA Head · Site Quality Head

**Subject:**
*Question on deviation-to-CAPA evidence burden*

**Body:**

```
Dear [Name],

I am reaching out personally because I am speaking with a small number of GMP Quality leaders in India about a specific problem: time lost reconstructing defensible evidence across deviation, RCA, CAPA, and audit preparation.

Verixa is running a founder-led GMP Design Partner Sprint: one facility, one bounded deviation-to-CAPA evidence workflow, 90 days. The goal is not a generic demo. The goal is to baseline the current burden, run selected historical / redacted / sample / controlled cases through a governed workflow, and deliver a Day-90 readout showing whether evidence burden, reviewer rework, and audit-prep friction were reduced.

Verixa is not claiming production validation or compliance certification. Customer QA owns intended use, validation, and go-live decisions.

Would a 20-minute workflow-fit conversation be worth scheduling?

Regards,
Vimal Veereshwarayya, PhD, RAC
Founder · Verixa · Navira Quality Systems Pvt Ltd
vimalv@verixa.ai
```

---

## EMAIL 2 · CEO / MD (use only for smaller companies)

**For:** CEO · MD · Founder at SMALL companies (under ~250 employees) where the CEO is reachable and likely involved in QA decisions

**Subject:**
*Question on deviation-to-CAPA evidence burden*

**Body:**

```
Dear [Name],

I am reaching out founder-to-founder. Verixa is speaking with a small number of GMP-focused India companies where lean QA teams may be losing time reconstructing deviation, RCA, CAPA, and audit-preparation evidence.

We are offering a 90-day GMP Design Partner Sprint: one facility, one bounded deviation-to-CAPA evidence workflow, measured before and after. The goal is a decision readout, not a generic software demo.

If your QA team has measurable burden in deviation/CAPA evidence assembly, a 20-minute workflow-fit conversation may be useful. If not, I will not push.

Regards,
Vimal Veereshwarayya, PhD, RAC
Founder · Verixa · Navira Quality Systems Pvt Ltd
vimalv@verixa.ai
```

---

## PHONE SCRIPT (T2 · 24–48 hrs after email)

**Use only after Email 1 or Email 2 has been sent.**

**Opening:**

> "Hello [Name], this is Vimal Veereshwarayya. I sent a short note about Verixa and a 90-day GMP evidence workflow sprint.
>
> I am not calling to sell a demo. I wanted to ask one question: do you currently have a deviation, RCA, CAPA, or audit-prep workflow where evidence assembly or reviewer rework is consuming measurable QA time?
>
> If yes, I would value 20 minutes to understand whether it is even a fit. If not, I will not push."

**If they ask "what does Verixa do?":**

> "Verixa helps GMP QA teams test whether a governed, human-reviewed AI evidence workflow can reduce deviation-to-CAPA burden. Phase 1 is one facility, one workflow, measured over 90 days. Production use would require your validation and QA approval."

**If they ask cost early:**

> "We usually start with a ₹3 lakh Evidence Mapping Sprint, credited to Phase 1. The full 90-day GMP Design Partner Sprint is ₹9 lakh — and as founding design partner pricing for the first two partners this year — but I would not recommend committing before we confirm the workflow pain and baseline metrics."

**If they say "send me information":**

> "Will do. I'll send the one-page summary today. The 20-minute call is what tells me whether the full deck is even relevant to your reality."

**If they say "not now":**

> "Understood. Mind if I check back in 60–90 days? In the meantime, if a deviation or CAPA workflow surfaces where evidence assembly is taking longer than it should, let me know — that's exactly the burden we measure."

---

## POST-FIT-CALL FOLLOW-UP EMAIL (T3 · same day or next day)

**Send only after a fit call has occurred AND the prospect requested more context.**

**Send the ONE-PAGER first.  Send the deck only if they explicitly ask.**

```
Dear [Name],

Thank you for the workflow-fit conversation today.

Attached:
1. Verixa GMP DP Sprint One-Pager (PDF) — sprint structure, deliverables, commercial offer, responsibility boundary.

[If they raised specific objections on the call, address them here in 2–3 sentences.  Otherwise omit this paragraph.]

Two next-step options:
1. Phase 0 Evidence Mapping Sprint scoping memo (₹3 lakh · 10 business days · 100% credited to Phase 1) — I draft to your team within 5 working days.
2. A second deeper-dive call with your Head of Validation / QMS Director / CSV consultant before Phase 0 commitment.

Which is most useful as the next step?

Regards,
Vimal Veereshwarayya, PhD, RAC
Founder · Verixa · Navira Quality Systems Pvt Ltd
vimalv@verixa.ai

Attachment:
- Verixa_GMP_DP_Sprint_OnePager_v1.0_Buyer_2026-06-23.pdf
```

**If they explicitly ask for the deck after receiving the one-pager, send:**
`Verixa_GMP_DP_Deck_v4.5_BuyerFirstSend_11slides_IN.pdf` (or `_US.pdf`)

---

## T4 RE-ENGAGEMENT (only if NO reply to T1 AND T2 after 10 days)

**One last gentle nudge.  Different angle from T1.  Do NOT send if any reply received.**

```
Dear [Name],

Quick follow-up. One question, no pitch:

How long did the team's last deviation → RCA → CAPA closure cycle take from event detection to evidence-pack approval?

If the honest answer is "longer than it should be," 20 minutes on the Verixa 90-day GMP sprint might be worth it.

If not, I will not reach out again.

Vimal
```

**After T4 silence:** mark "no response · Q4 silent revisit only on warm signal" in tracker.  Do NOT pursue further.

---

## STOP CONDITIONS

| Signal | Action |
|---|---|
| Positive reply (yes, let's talk) | Stop sequence · book fit call · log in tracker |
| Calendar booked directly | Stop sequence · log |
| "Send more info first" | Send T3 immediately with **ONE-PAGER ONLY** · respond personally |
| "Wrong person" | Stop · ask for referral · log referral name in tracker · start new outreach to referral |
| "Not now / Q4" | Stop T1–T4 · do NOT auto-enroll in nurture (killed) · re-evaluate at warm signal only |
| "Do not contact / unsubscribe" | Stop ALL communication · log DNC · suppress for all future sequences |
| Bounce | Stop sequence · attempt email re-verify (Apollo · LinkedIn) · pursue warm intro only |
| No reply through T4 (Day 14) | Stop active sequence · do NOT auto-nurture · only re-engage on warm signal |

---

## SEND-WINDOW + DISCIPLINE RULES

- **Send window:** Mon–Fri primary · Sat optional · Sun off · IST 9–11am preferred for opens
- **Volume cap:** ≤5–8 personalized emails per day (founder-led discipline · not bulk)
- **No bulk-send via Apollo for the 30-list** — these are founder-led 1-to-1
- **First attachment:** ONE-PAGER ONLY · never the deck on first send
- **Deck send:** only after fit call OR explicit prospect ask for the deck
- **Never claim:** validated · compliant · audit-ready · inspection-ready · GxP-ready · regulator-safe
- **Never pitch ₹9 lakh on T1 or T2** — fit call discovery first
- **Never target ex-employers** (BMS · Genentech · Alumis · Arcellx) — intro/reference only
- **Never use WhatsApp before T1 email + prior relationship OR explicit warm intro** — formality matters in Indian QA-leader context

---

## PRIVACY + OPT-OUT (jurisdiction-dependent · verify before high-volume send)

- **India DPDP Act 2023:** B2B business-email outreach is generally permitted but requires lawful basis · India counsel signoff recommended before scaling
- **Opt-out:** Every email must include implicit opt-out via "I will not push" language · honor every "do not contact" request immediately and permanently
- **Suppression list:** Maintain separate DNC log · cross-check before any future outreach
- **CRM retention:** Personal contact details (email · phone · WhatsApp) stored only for active-outreach period · purge on disqualification or DNC
- **Enriched email use:** Apollo-enriched business emails are work emails · NOT personal data under DPDP scope · still apply opt-out discipline
- **WhatsApp:** Treat as consent-required channel · do NOT cold-message · only use after email reply, prior relationship, or warm intro

**Recommendation:** India counsel signoff on the outreach motion BEFORE sending to >10 contacts.

---

## COMPANION FILES

| File | Location |
|---|---|
| Playbook | `Verixa GTM/India_Founder_Outreach/1_Internal_Execution/Verixa_India_Founder_Outreach_Playbook_v1.1_2026-06-23.md` |
| Re-ranked 30-account list (12/10/8) | `Verixa GTM/India_Founder_Outreach/1_Internal_Execution/Verixa_India_30_Account_Target_List_v1.1_2026-06-23.csv` |
| ICP profiles + enrichment | `Verixa GTM/India_Founder_Outreach/1_Internal_Execution/Verixa_India_ICP_Profiles_and_Enrichment_v1.0_2026-06-21.md` (carried over from v1.0) |
| CRM tracker (with verification fields) | `Verixa GTM/India_Founder_Outreach/1_Internal_Execution/Verixa_India_Founder_Outreach_Tracker_v1.1_2026-06-23.md` |
| Buyer one-pager (T3 attachment) | `Verixa GTM/India_Founder_Outreach/2_Buyer_Facing/Verixa_GMP_DP_Sprint_OnePager_v1.0_Buyer_2026-06-23.md` (+ PDF render) |
| Buyer deck (deeper-dive only) | `Verixa GTM/India_Founder_Outreach/2_Buyer_Facing/Verixa_GMP_DP_Deck_v4.5_BuyerFirstSend_11slides_IN.pdf` (or `_US.pdf`) |

---

**Vimal Veereshwarayya, PhD, RAC**
Founder · Verixa (Navira Quality Systems Pvt Ltd)
23 June 2026